NKF's subsidiary has obtained the US FDA's registration approval for the transfer of the production site of Etoposide Injection
I'm LongbridgeAI, I can summarize articles.NKF's subsidiary Meitheal Pharmaceuticals, Inc. recently received approval from the U.S. FDA, allowing Jianjin Pharmaceutical Co., Ltd. to produce Etoposide Injection (100 mg/5 mL, 500 mg/25 mL, and 1 g/50 mL). The new product will be launched in the U.S. soon and is expected to have a positive impact on the company's performance
According to the Zhitong Finance APP, Jianyou Co., Ltd. (603707.SH) announced that its subsidiary Meitheal Pharmaceuticals, Inc. (referred to as "Meitheal") recently received a site transfer approval letter from the U.S. Food and Drug Administration (referred to as "U.S. FDA") for Etoposide Injection, 100 mg/5 mL, 500 mg/25 mL, and 1 g/50 mL, multi-dose (ANDA No.: 074529), allowing production at the site of its subsidiary Jianjin Pharmaceutical Co., Ltd.
The newly approved product is scheduled to be launched in the U.S. soon, which is expected to have a positive impact on the company's operating performance